Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
364 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (33)
  • (-) Currently Recruiting (4)
  • Closed (29)

Medical Condition

  • Show all (364)
  • Addiction (2)
  • Allergy, Asthma, & Immunology (1)
  • Autoimmune Disorders (2)
  • Blood Disorders (1)
  • Bone & Muscle (2)
  • Cancer (109)
    • Bladder Cancer (1)
    • Brain Cancer (9)
    • Breast Cancer (7)
    • Gastrointestinal (3)
    • Gynecologic Cancer (9)
    • Kidney Cancer (1)
    • Leukemia (8)
    • Liver Cancer (2)
    • Lung Cancer (6)
    • Lymphoma (12)
    • Multiple Myeloma (8)
    • Pancreatic Cancer (7)
    • Prostate Cancer (6)
    • (-) Skin Cancer (2)
      • Melanoma (2)
  • Child Development (1)
  • COVID-19 (Coronavirus) (10)
  • Diabetes (9)
  • Ear, Nose and Throat (6)
  • Endocrine & Metabolic Disease (2)
  • Gastrointestinal and Digestive Diseases (3)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (44)
  • Heart Disease (25)
  • Infectious Disease (11)
  • Liver Disease (14)
  • Lung Disease (3)
  • Neurological Disorders (45)
  • Nutrition (1)
  • Obesity (8)
  • Obstetrics & Gynecology (12)
  • Pediatrics (26)
    • Cancer (4)
    • (-) Child and Adolescent Health (2)
  • Psychiatric Disorders (8)
  • Rehabilitation (1)
  • Stroke (2)
  • Transplant (15)
Displaying 1 - 4 of 4

Study of DYP688 in Patients with Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to identify the safest and most tolerable dose of the study drug, DYP688 that can be given to patients. Also to evaluate how well DYP688 might work in treating certain types of cancer including metastatic uveal melanoma and other melanomas with GNAQ/11 mutations (or genetic changes to the gene GNAQ/11). Metastatic means the…
Read More

Study of V940 Plus Pembrolizumab in Patients With High-Risk Melanoma

Condition: Skin Cancer / Melanoma
Investigator: Benjamin Izar, MD
Status: Currently Recruiting
The purpose of this study is to compare V940 plus pembro given after surgery to a placebo plus pembro given after surgery and to study how effective the study drug is. A placebo looks like a study drug, but it has no active ingredients. V940 has not yet been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but it has not…
Read More

Kids with Iron Deficiency and Scoliosis (KIDS) Study

Condition: Pediatrics / Child and Adolescent Health
Investigator: Lisa Eisler, MD
Status: Currently Recruiting
We are studying the effects of iron supplementation in patients undergoing surgery for scoliosis. If you are scheduled or are planning to schedule a scoliosis surgery in greater than 3 months, please contact us to determine eligibility.
Read More

Cognition and Psychosocial Functioning During Puberty Blocking

Condition: Pediatrics / Child and Adolescent Health
Investigator: Ilene Fennoy, MD
Status: Currently Recruiting
We know that puberty is a major time of change! Adolescents develop new decision-making skills and independence. It is possible that some of these changes are due to the hormonal changes during puberty. One of the ways we treat transgender and gender non-conforming teens is to suppress or "block" puberty. We know that this is a safe thing to do…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science